Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 1, 2026
Context: The filing serves as a Regulation FD disclosure regarding upcoming investor meetings scheduled between September 1, 2026, and September 30, 2026. The primary purpose is to reaffirm financial guidance for the fiscal year ending December 31, 2026.
Key Financial Metrics and Guidance
The filing provides specific forward-looking guidance for Fiscal Year 2026 (FY 2026) but does not report historical revenue, profit, cash flow, or debt figures for the current period.
- GAAP Diluted EPS Guidance: At least $6.52
- Adjusted (Non-GAAP) EPS Guidance: At least $9.00
- Reconciliation Items (GAAP to Adjusted):
- Amortization of identifiable intangibles: $0.30
- Put/call valuation adjustments: $1.47
- Value creation initiatives: $1.27
- Impairment charges: $0.17
- Cumulative net tax impact: ($0.73)
Note: The filing text does not provide clear values for total revenue, operating margins, total debt, or liquidity positions.
Material Changes and Outlook
Guidance Consistency: The FY 2026 guidance reaffirmed in this filing is consistent with the press release issued on July 29, 2026. Management does not expect changes to the Adjusted (non-GAAP) EPS guidance.
Potential GAAP Variance: Management expects potential changes to the FY 2026 GAAP EPS guidance due to ongoing value creation and other strategic initiatives.
Medicare Advantage Star Ratings: The Company will not comment on 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028) until the Centers for Medicare and Medicaid Services (CMS) releases final data in October 2026.
Risks and Contingencies
Forward-Looking Statements: The report contains forward-looking statements subject to risks, uncertainties, and assumptions. These are not guarantees of future performance.
Non-GAAP Limitations: Adjusted EPS is not intended to normalize earnings, eliminate volatility, or represent future performance. It may differ from similarly titled measures used by other companies and should not be viewed as a substitute for GAAP EPS.
Unrecognized Items: The guidance excludes the impact of value changes to items that have not yet been recognized or cannot currently be reasonably estimated.
Investor Verification Checklist
- Verify the final 2027 Medicare Advantage Star Ratings data when released by CMS in October 2026.
- Monitor upcoming investor meetings (September 1–30, 2026) for updates on value creation initiatives that may impact GAAP EPS.
- Review the reconciliation of GAAP to Adjusted EPS to understand the specific impact of put/call valuation adjustments and impairment charges.
- Confirm that the "at least" language in the guidance implies a floor rather than a precise target for earnings.